TET2 and non-small cell lung carcinoma: Furthermore, we found the expression of TET2 was significantly downregulated in 32 clinical specimens collected from NSCLC patients with continued disease progression after osimertinib treatment, compared with those pre-treatment NSCLC samples (Fig. 1f, g, and Supplementary Table 1), suggesting that the downregulation of TET2 was associated with the acquired resistance to EGFR-TKIs.